EU committee recommends omega-3 supplements during pregnancy

Pregnant women should take a daily supplement of omega-3 acids, an EU supported consensus committee has recommended. The supplement would increase the likelihood of a healthy birth and boost child development. The committee, composed of more than 50 nutritional experts from the EU-funded projects Perinatal Lipid Nutrition Group (PeriLip) and Early Nutrition Programming (EARNEST), said it had found that women who included DHA in their diet had healthier pregnancies, that their children had healthier birth weights and that they were less likely to give birth prematurely.

According to the recommendation, also supported by seven international scientific organisations, pregnant and nursing mothers should take 200 mailgrams per day of a form of omega-3 fatty acids called docosahexaenoic acid (DHA), which can be found in fatty fish such as salmon and mackerel. DHA intake has been linked to brain and eye development.

"Based on the systematic reviews of the available evidence, this EU-supported group of international experts unanimously concluded that women should have a regular supply of the omega-3 fatty acid DHA during pregnancy and the breastfeeding period, as it is of great importance for the child's health," told Professor Berthold Koletzko, from the Children's Hospital at the University of Munich, Germany.

The committee found however that the diets of western mothers tended to be low in foods that would provide the necessary dose. The experts believe that this could be explained by limited levels of awareness of the role of omegas in infant development.

DHA supplements have been linked with impacts on various ailments and conditions. Recent evidence has suggested that they can ease the symptoms of disorders such as schizophrenia, depression, dyslexia and Alzheimer's.

The Food Standards Agency currently advises that the consumption of two portions of fatty sea fish per week, necessary to gain the recommended levels of DHA, is generally safe for pregnant and breast-feeding women.

It also advises that DHA can also be found in other forms, including in supplements.

For further information, please visit:

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...